Rein Therapeutics Inc (RNTX) Stock Price, Quote & News

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 802 1989

Website: www.reintx.com

Address:

12407 N. Mopac Expy., Suite 250 #390, Austin, United States

MagelaMason Jul. 18 at 2:35 PM

$RNTX

0 · Reply

Tunes444 Jul. 18 at 2:25 PM

$RNTX Need some news..

0 · Reply

Fearrr Jul. 18 at 2:24 PM

$RNTX

0 · Reply

Tunes444 Jul. 17 at 1:45 PM

$RNTX Added to the watchlist

0 · Reply

Tester87100 Jul. 16 at 2:42 PM

$RNTX

0 · Reply

LebronBOOM Jul. 16 at 2:33 PM

$RNTX Diving into these guys more!

0 · Reply

StayinOuttaTheRed Jul. 16 at 2:32 PM

$RNTX Someone in discord gave me the rundown of this one lets see what happens

0 · Reply

PaoloWorld Jul. 16 at 2:32 PM

$RNTX Whats the update here?

0 · Reply

Viiinnkkaa Jul. 16 at 2:30 PM

$RNTX Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026

0 · Reply

IsaacP2 Jul. 16 at 2:29 PM

$RNTX !

0 · Reply

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:18 PM EDT - 5 weeks ago

US FDA puts on hold Rein Therapeutics' lung disease drug trial

May 27, 2025, 7:00 AM EDT - 7 weeks ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQV

May 19, 2025, 4:51 PM EDT - 2 months ago

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 15, 2025, 4:09 PM EDT - 2 months ago

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 2 months ago

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025, 7:00 AM EDT - 2 months ago

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Apr 30, 2025, 4:05 PM EDT - 2 months ago

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 28, 2025, 7:00 AM EDT - 2 months ago

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Apr 23, 2025, 7:00 AM EDT - 3 months ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 15, 2025, 7:00 AM EDT - 3 months ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 7, 2025, 4:17 PM EDT - 3 months ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MagelaMason Jul. 18 at 2:35 PM

$RNTX

0 · Reply

Tunes444 Jul. 18 at 2:25 PM

$RNTX Need some news..

0 · Reply

Fearrr Jul. 18 at 2:24 PM

$RNTX

0 · Reply

Tunes444 Jul. 17 at 1:45 PM

$RNTX Added to the watchlist

0 · Reply

Tester87100 Jul. 16 at 2:42 PM

$RNTX

0 · Reply

LebronBOOM Jul. 16 at 2:33 PM

$RNTX Diving into these guys more!

0 · Reply

StayinOuttaTheRed Jul. 16 at 2:32 PM

$RNTX Someone in discord gave me the rundown of this one lets see what happens

0 · Reply

PaoloWorld Jul. 16 at 2:32 PM

$RNTX Whats the update here?

0 · Reply

Viiinnkkaa Jul. 16 at 2:30 PM

$RNTX Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026

0 · Reply

IsaacP2 Jul. 16 at 2:29 PM

$RNTX !

0 · Reply

LondonLeaves9845 Jul. 16 at 2:28 PM

$RNTX Following Rein - Looking for an update on their trials

0 · Reply

ThoughtsOnThis Jul. 16 at 2:26 PM

$RNTX Any updates here?

0 · Reply

Tunes444 Jul. 16 at 2:25 PM

$RNTX Green on the day

0 · Reply

Tunes444 Jul. 15 at 5:27 PM

$RNTX Just added to my list

0 · Reply

Tunes444 Jul. 15 at 4:53 PM

$RNTX

0 · Reply

LebronBOOM Jul. 15 at 4:53 PM

$RNTX Missed the stockholders meeting back in June, any highlights?

0 · Reply

PaoloWorld Jul. 15 at 4:52 PM

$RNTX Anyone has insights on how things are going with these guys?

0 · Reply

Tester87100 Jul. 15 at 4:50 PM

$RNTX >>

0 · Reply

BigRodddd Jul. 15 at 4:50 PM

$RNTX Saw these guys in a discord a little while back seem like a cool company just extremely quiet on news flow atm

0 · Reply

StocksPlusStuffers Jul. 15 at 4:48 PM

$RNTX Hopefully we can get an update on the first patient being dosed in their P2 trial

0 · Reply

Fearrr Jul. 15 at 4:48 PM

$RNTX Just waiting for the next PR to cross the line

0 · Reply

Ferg500 Jul. 15 at 4:48 PM

$RNTX last piece of news we got really is 'Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF'

0 · Reply

Market Cap	31.90M
Revenue (ttm)	0.00
Net Income (ttm)	-62.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	8,310
Avg Vol	40,584
Day's Range	N/A - N/A
Shares Out	22.15M
Stochastic %K	9%
Beta	1.22
Analysts	Strong Sell
Price Target	$7.00